



Attorney Docket No.: GEN/005 (AV 5 US)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Ronan C. O'Hagan et al.  
Application No. : 10/540,828 Confirmation No.: 2251  
Filed : December 23, 2003  
For : *IN VIVO* METHODS FOR VALIDATING THE ROLE  
OF A TUMOR MAINTENANCE GENE  
Group Art Unit : Not Yet Assigned  
Examiner : Not Yet Assigned

New York, New York  
February 4, 2008

Mail Stop Amendment  
Hon. Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make the  
following patents and publications of record in the above-identified patent application:\*

**U.S. Patents**

<u>Patent No.</u>	<u>Issue Date</u>	<u>Applicant(s)</u>
4,736,866	04/12/88	Leder et al.
5,919,997	07/06/99	Beach et al.
US2002/0086356 A1	07/04/02	Tuschl et al.

---

\*A completed Form PTO/SB/08a listing these documents is attached hereto.

### Foreign Publications

<u>Publication No.</u>	<u>Publication Date</u>	<u>Applicant(s)</u>
WO 99/32619	07/01/99	Carnegie Institute of Washington
WO 99/53050	10/21/99	Common Health Scientific and Industrial Research Organization
WO 01/09308	02/08/01	Dan-Farber Cancer Institute Inc.
WO 01/29058	04/26/01	University of Massachusetts
WO 01/36646	05/25/01	Cancer Research Campaign Technology Limited
WO 01/68836	09/20/01	Genetica, Inc.; and Cold Spring Harbor Laboratory

### Other Documents

Arts *et al.*, "Adenoviral vectors expressing siRNAs for discovery and validation of gene function," *Genome Research*, 13, pp. 2325-2332 (2003)

Brummelkamp *et al.*, "A system for stable expression of short interfering RNAs in mammalian cells," *Science*, 296, pp. 550-553 (2002)

Camper and Tilghman, "Postnatal repression of the  $\alpha$ -fetoprotein gene is enhancer independent," *Genes Dev.*, 3, pp. 537-546 (1989)

Chin *et al.*, "Cooperative effects of *INK4a* and *ras* in melanoma susceptibility *in vivo*," *Genes Devel.*, 11, pp. 2822-34 (1997)

Davies *et al.*, "Mutations of the BRAF gene in human cancer " *Nature*, 417, pp. 949-54 (2002)

Edlund *et al.*, "Cell-specific expression of the rat insulin gene: evidence for role of two distinct 5' flanking element," *Science*, 230, pp. 912-916 (1985)

Elbashir *et al.*, "Analysis of gene function in somatic mammalian cells using small interfering RNAs," *Methods*, 26, pp. 199-213 (2002)

Hannon, "RNA interference," *Nature*, 418, pp. 244-251 (2002)

Kessel and Gruss, "Murine Development control genes," *Science*, 249, pp. 374-379 (1990)

Kumar *et al.*, "High-throughput selection of effective RNAi probes for gene silencing," 13, pp. 2333-2340 (2003)

McManus and Sharp, "Gene silencing in mammals by small interfering RNAs," *Nature Reviews*, 3, pp. 737-747 (2002)

Tuschl, "Expanding small RNA interference," *Nature Biotechnology*, 20, pp. 446-448 (2002)

Applicants respectfully request that these documents be (1) considered by the Examiner prior to issuance of any patent from this application; and (2) printed on any patent that may issue from this application. Applicants also request that a copy of enclosed Form PTO/SB/08A, as considered and initialed by the Examiner, be returned with the next communication.

This Statement is submitted before the mailing of a first Office Action on the merits. In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee. If for any reason any additional fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075, Order No. 001581-0151.

Respectfully submitted,



---

Jane T. Gunnison (Reg. No. 38,479)

Connie Wong (Reg. No. L0104)

Attorneys for Applicants

ROPES & GRAY LLP

Customer No. 1473

1211 Avenue of the Americas

New York, New York 10036

Tel.: (212) 596-9000

Fax: (212) 596-9090